Products
Gulgafafusp Biosimilar Fusion Protein (GLP-1 Receptor) for Research
Cat No.: GMP-Bios-INN-1225
Anti-GLP1R therapeutic antibody (Pre-made Gulgafafusp biosimilar,Fusion Protein (whole mAb with protein)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Gulgafafusp (development codes GMA-102/GMA-105) is a fusion protein targeting GLP-1 receptor. It is developed by Gmax Biopharm for type 2 diabetes mellitus. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1225-1mg | 1mg | 3090 |
| GMP-Bios-INN-1225-10mg | 10mg | |
| GMP-Bios-INN-1225-100mg | 100mg | |
| GMP-Bios-INN-1225-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Gulgafafusp biosimilar, Fusion Protein (whole mAb with protein) targeting GLP1R: Recombinant therapeutic protein targeting GLP1R/Glucagon-like peptide 1 receptor/GLP-1 receptor/GLP-1-R |
| INN Name | Gulgafafusp |
| Target | GLP1R |
| Format | Fusion Protein (whole mAb with protein) |
| Derivation | na |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | na |
| Companies | Gmax Biopharm |
| Conditions Approved | na |
| Conditions Active | Type 2 diabetes mellitus |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
